Company: TYRA
Filing Date: 2025-01-29
Form Type: 8-K
Source: 0001193125-25-015646
Chunk: 0

Company: Tyra Biosciences, Inc.
Filing Date: 2025-01-29
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

On January 28, 2025, in connection with the appointment of a new director to the Board of Directors (the “ Board”) of Tyra Biosciences, Inc. (the “ Company”), Nina Kjellson resigned from the Board and the Compensation Committee of the Board effective as of January 29, 2025 (the “ Effective Date”). Ms. Kjellson’s resignation from the Board and the Compensation Committee was not made in connection with a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

On the Effective Date, the Board appointed Adele M. Gulfo as a director of the Board, filling the Class I vacancy on the Board resulting from Ms. Kjellson’s resignation. In addition, Ms. Gulfo was appointed to the Compensation Committee of the Board. Ms. Gulfo’s appointments to the Board and the Compensation Committee thereof were effective as of the Effective Date and were made based upon the recommendation of the Board’s Nominating and Corporate Governance Committee.

Ms. Gulfo, 62, served as the Chief Executive Officer, Biopharma Commercial Unit of Sumitomo Pharma America, Inc. from July 2023 to October 2024. Previously, she served as Chief Commercial and Business Development Officer at Sumitovant Biopharma, Inc. since December 2019. Sumitovant Biopharma, a privately held company affiliated with Sumitomo Dainippon Pharma Co., Ltd., operates five biopharmaceutical companies acquired from Roivant Sciences Ltd. in December 2019, which includes Myovant Sciences Ltd. From May 2020 to March 2021, Ms. Gulfo served as the interim Chief Commercial Officer of Myovant Sciences. From May 2018 to December 2019, Ms. Gulfo served as Chief of Commercial Development of Roivant Sciences. Prior to joining Roivant Sciences in May 2018, Ms. Gulfo served as Executive Vice President, Chief Strategy Officer and Head of Global Commercial Development for Mylan N. V. from January 2014 to January 2018. Before joining Mylan, Ms. Gulfo spent five years at Pfizer Inc. in a number of executive positions, including President and General Manager, U. S. Primary Care. She was also Country Manager for